Goldman Sachs believes the grade 4 liver transaminase elevation safety event disclosed by Intellia Therapeutics (NTLA) for the Phase 3 MAGNITUDE study potentially places nex-z’s commercial positioning further in question given the CRISPR therapy’s lack of an established long-term safety profile. The therapy has shown limited differentiation on efficacy versus siRNA competitors, the analyst tells investors in a research note. Goldman has a Sell rating on Intellia with an $8 price target The stock in morning trading is down 28%, or $2.70, to $6.96.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $39 from $43 at BofA
- Intellia adverse event could resurface questions, says JPMorgan
- Intellia discloses grade 4 liver transaminase elevation in MAGNITUDE trial
- Positive Outlook for Intellia Therapeutics Despite Safety Concerns in MAGNITUDE Trial
- Intellia Therapeutics: Buy Rating Affirmed Despite Safety Concerns in MAGNITUDE Study